217 related articles for article (PubMed ID: 37575240)
1. Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types.
Yan T; Xie Y; Liu Y; Shan Y; Wu X; Wang J; Zuo YG; Zhang Z
Front Immunol; 2023; 14():1194088. PubMed ID: 37575240
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Dupilumab in Patients With Bullous Pemphigoid.
Zhao L; Wang Q; Liang G; Zhou Y; Yiu N; Yang B; Zhang G; Li W; Feng S; Shang P; Chen X; Zhu X; Zheng J; Pan M; Wang M
JAMA Dermatol; 2023 Sep; 159(9):953-960. PubMed ID: 37531116
[TBL] [Abstract][Full Text] [Related]
3. Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review.
Liang J; Abulikemu K; Maolidan ; Hu F; Zhao J; Qiu Y; Wang Q; Sang Y; Hong Y; Kang X
Int Immunopharmacol; 2023 Mar; 116():109788. PubMed ID: 36731156
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.
Zhang Y; Xu Q; Chen L; Chen J; Zhang J; Zou Y; Gong T; Ji C
Front Immunol; 2021; 12():738907. PubMed ID: 34721404
[TBL] [Abstract][Full Text] [Related]
5. Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.
Cao P; Xu W; Zhang L
Front Immunol; 2022; 13():928621. PubMed ID: 35769474
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid.
Yang J; Gao H; Zhang Z; Tang C; Chen Z; Wang L; Yang F; Chen S; He S; Liu S; Tang L; Xu Y; Hu Y; Ma L; Zhao Y; Luo X
Dermatol Ther; 2022 Aug; 35(8):e15648. PubMed ID: 35715972
[TBL] [Abstract][Full Text] [Related]
7. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.
Murrell DF; Joly P; Werth VP; Ujiie H; Worm M; Mangold AR; Avetisova E; Maloney J; Laws E; Mortensen E; Dubost-Brama A; Shabbir A
Adv Ther; 2024 Jul; 41(7):2991-3002. PubMed ID: 38443648
[TBL] [Abstract][Full Text] [Related]
8. Advancements in Bullous Pemphigoid Treatment: A Comprehensive Pipeline Update.
Karakioulaki M; Eyerich K; Patsatsi A
Am J Clin Dermatol; 2024 Mar; 25(2):195-212. PubMed ID: 38157140
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.
Abdat R; Waldman RA; de Bedout V; Czernik A; Mcleod M; King B; Gordon S; Ahmed R; Nichols A; Rothe M; Rosmarin D
J Am Acad Dermatol; 2020 Jul; 83(1):46-52. PubMed ID: 32179082
[TBL] [Abstract][Full Text] [Related]
10. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.
Alexandre M; Bohelay G; Gille T; Le Roux-Villet C; Soued I; Morin F; Caux F; Grootenboer-Mignot S; Prost-Squarcioni C
Front Immunol; 2022; 13():874108. PubMed ID: 35514989
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study.
Huang D; Zhang Y; Yu Y; Jiang Y; Kong L; Ding Y; Shi Y; Gao Y
Int Immunopharmacol; 2023 Dec; 125(Pt A):111157. PubMed ID: 37925949
[TBL] [Abstract][Full Text] [Related]
12. Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study.
Hu L; Huang R; Jiang F; You S; Wu Q
Immun Inflamm Dis; 2023 Jul; 11(7):e924. PubMed ID: 37506153
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid.
Vassallo C; Somenzi A; De Amici M; Barruscotti S; Brazzelli V
Dermatol Ther; 2022 Dec; 35(12):e15946. PubMed ID: 36259470
[TBL] [Abstract][Full Text] [Related]
14. Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?
Russo R; Capurro N; Cozzani E; Parodi A
J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743438
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin in patients with bullous pemphigoid insufficient response to corticosteroids: Nationwide post-marketing surveillance in Japan.
Ujiie H; Arakawa M; Aoyama Y
J Dermatol Sci; 2023 Jan; 109(1):22-29. PubMed ID: 36697305
[TBL] [Abstract][Full Text] [Related]
16. Enzyme-linked immunosorbent assay in autoimmune blistering diseases: preliminary experience of the Dermatology Department of Cagliari.
Atzori L; Deidda S; Aste N
G Ital Dermatol Venereol; 2008 Feb; 143(1):1-8. PubMed ID: 18833046
[TBL] [Abstract][Full Text] [Related]
17. Erythrodermic Bullous Pemphigoid in Skin of Color Treated With Dupilumab.
Sanfilippo E; Gonzalez Lopez A; Saardi KM
J Drugs Dermatol; 2023 Jul; 22(7):685-686. PubMed ID: 37410035
[TBL] [Abstract][Full Text] [Related]
18. Case report: Dupilumab for the treatment of bullous pemphigoid.
Wang M; Wang J; Shi B
Dermatol Ther; 2022 Jul; 35(7):e15541. PubMed ID: 35478478
[TBL] [Abstract][Full Text] [Related]
19. [Interpretation of 2021 French Guidelines for the Therapeutic Management of Bullous Pemphigoid].
Wang SH; Zuo YG
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Oct; 44(5):828-836. PubMed ID: 36325781
[TBL] [Abstract][Full Text] [Related]
20. Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study.
Tsai YJ; Cho YT; Chu CY
Am J Clin Dermatol; 2022 Jul; 23(4):571-585. PubMed ID: 35579853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
